Combining plasma-based biosources to predict treatment response in NSCLC patients
- PMID: 30010765
- DOI: 10.1093/annonc/mdy246
Combining plasma-based biosources to predict treatment response in NSCLC patients
Comment on
-
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765. Ann Oncol. 2018. PMID: 29216356 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
